Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience-Reference-Cited by-同舟云学术

Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience

Published:2024 Issue:5 Volume:35 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Wijaya Silvana Talisa¹^ORCID,Ngoi Natalie YL¹^ORCID,Loh Jerold WZ¹^ORCID,Tan Tuan Zea²³^ORCID,Lim Diana⁴^ORCID,Khan Irfan Sagir⁴^ORCID,Thian Yee Liang⁵^ORCID,Lai Alexa¹^ORCID,Ang Bertrand WL⁵^ORCID,Tong Pearl⁶^ORCID,Ng Joseph⁶^ORCID,Low Jeffrey JH⁶^ORCID,Ilancheran Arunachalam⁶^ORCID,Lim Siew Eng¹^ORCID,Lim Yi Wan¹^ORCID,Tan David SP²⁷⁸^ORCID

Affiliation:

1. Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore.

2. Cancer Science Institute of Singapore, National University of Singapore, Singapore.

3. Genomics and Data Analytics Core (GeDaC), Cancer Science Institute of Singapore, National University of Singapore, Singapore.

4. Department of Pathology, National University Health System, Singapore.

5. Department of Diagnostic Imaging, National University Health System, Singapore.

6. Division of Gynaecologic Oncology, Department of Obstetrics & Gynaecology, National University Hospital, Singapore.

7. Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

8. NUS Centre for Cancer Research (N2CR), National University of Singapore, Singapore.

Funder

National Medical Research Council

Pangestu Family Foundation Gynaecological Cancer Research Fund

Publisher

XMLink

Link

https://ejgo.org/pdf/10.3802/jgo.2024.35.e69

Reference41 articles.

1. Annual Report of the Committee on Gynecologic Oncology, Japan Society of Obstetrics and Gynecology: Patient Annual Report for 2014 and Treatment Annual Report for 2009

2. Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012

3. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives

4. IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

5. Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers